Sun Pharmaceutical Industries Future Growth

Future criteria checks 1/6

Sun Pharmaceutical Industries is forecast to grow earnings and revenue by 15.9% and 9.7% per annum respectively. EPS is expected to grow by 14.8% per annum. Return on equity is forecast to be 17% in 3 years.

Key information

15.9%

Earnings growth rate

14.8%

EPS growth rate

Pharmaceuticals earnings growth	18.4%
Revenue growth rate	9.7%
Future return on equity	17.0%
Analyst coverage	Good
Last updated	08 May 2024

Recent future growth updates

Recent updates

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Mar 13

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Feb 03

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Jan 05

Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely

Dec 18

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Oct 04

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Jul 03

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Jun 15

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Mar 14

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50

Feb 03

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

Dec 09

Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?

Oct 13

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely

Sep 04

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Aug 05

Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Jul 12

Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?

Jun 02

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Apr 28

Are Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Investors Paying Above The Intrinsic Value?

Apr 09

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.00

Feb 02

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Using Too Much Debt?

Feb 02

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Jan 19

Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Dec 27

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly

Nov 04

Here's Why I Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Oct 21

Calculating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Sep 27

Earnings and Revenue Growth Forecasts

NSEI:SUNPHARMA - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	635,840	155,684	138,142	N/A	2
3/31/2026	593,050	129,651	123,789	N/A	30
3/31/2025	538,436	112,656	104,885	N/A	33
3/31/2024	485,376	93,041	91,808	N/A	33
12/31/2023	474,446	89,063	N/A	N/A	N/A
9/30/2023	463,049	85,485	96,498	116,171	N/A
6/30/2023	450,648	84,352	N/A	N/A	N/A
3/31/2023	438,857	84,736	28,738	49,593	N/A
12/31/2022	424,018	42,119	N/A	N/A	N/A
9/30/2022	410,239	41,047	24,284	40,183	N/A
6/30/2022	396,975	38,894	N/A	N/A	N/A
3/31/2022	386,545	32,727	74,895	89,845	N/A
12/31/2021	377,307	64,441	N/A	N/A	N/A
9/30/2021	367,044	62,378	67,751	82,511	N/A
6/30/2021	356,316	60,036	N/A	N/A	N/A
3/31/2021	334,981	29,038	50,002	61,704	N/A
12/31/2020	331,601	24,095	N/A	N/A	N/A
9/30/2020	324,782	14,706	33,332	47,270	N/A
6/30/2020	320,484	7,219	N/A	N/A	N/A
3/31/2020	328,375	37,649	50,128	65,548	N/A
12/31/2019	318,165	40,010	N/A	N/A	N/A
9/30/2019	314,018	43,293	26,411	43,521	N/A
6/30/2019	302,161	29,956	N/A	N/A	N/A
3/31/2019	290,659	26,654	-10,164	21,965	N/A
12/31/2018	288,052	34,379	N/A	N/A	N/A
9/30/2018	277,182	24,380	N/A	N/A	N/A
6/30/2018	275,048	35,690	N/A	N/A	N/A
3/31/2018	264,155	20,957	19,464	39,072	N/A
12/31/2017	263,811	20,763	N/A	N/A	N/A
9/30/2017	276,530	31,827	N/A	N/A	N/A
6/30/2017	295,310	45,057	N/A	N/A	N/A
3/31/2017	313,081	69,644	N/A	70,822	N/A
12/31/2016	319,185	73,270	N/A	N/A	N/A
9/30/2016	311,431	74,000	N/A	N/A	N/A
6/30/2016	297,512	61,937	N/A	N/A	N/A
3/31/2016	281,086	45,457	N/A	66,859	N/A
12/31/2015	266,281	38,915	N/A	N/A	N/A
9/30/2015	264,670	28,702	N/A	N/A	N/A
6/30/2015	276,422	38,150	N/A	N/A	N/A
3/31/2015	273,920	45,394	N/A	56,157	N/A
12/31/2014	170,765	59,141	N/A	N/A	N/A
9/30/2014	170,835	60,202	N/A	N/A	N/A
6/30/2014	165,250	58,100	N/A	N/A	N/A
3/31/2014	160,804	31,415	N/A	39,592	N/A
12/31/2013	150,933	26,104	N/A	N/A	N/A
9/30/2013	136,587	19,606	N/A	N/A	N/A
6/30/2013	120,629	9,364	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUNPHARMA's forecast earnings growth (15.9% per year) is above the savings rate (6.7%).

Earnings vs Market: SUNPHARMA's earnings (15.9% per year) are forecast to grow slower than the Indian market (17.4% per year).

High Growth Earnings: SUNPHARMA's earnings are forecast to grow, but not significantly.

Revenue vs Market: SUNPHARMA's revenue (9.7% per year) is forecast to grow slower than the Indian market (9.8% per year).

High Growth Revenue: SUNPHARMA's revenue (9.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SUNPHARMA's Return on Equity is forecast to be low in 3 years time (17%).

Sun Pharmaceutical Industries Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target increased by 9.3% to ₹1,453

Price target increased by 7.0% to ₹1,229

Recent updates

Sun Pharmaceutical Industries Limited Announces Executive Changes

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 16.33% stake in Surgimatix, Inc for $3.1 million.

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Dividend increased to ₹8.50

Price target increased by 9.3% to ₹1,453

Third quarter 2024 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited Approves Interim Dividend for the Financial Year 2023-24, Payable on or Before February 23, 2024

Sun Pharmaceutical Industries Limited to Report Q3, 2024 Results on Jan 31, 2024

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely

Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm

Sun Pharmaceutical Industries Limited Announces Management Changes

Second quarter 2024 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited to Report Q2, 2024 Results on Nov 01, 2023

Sun Pharmaceutical Industries Limited Announces Presentation of Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 37.76% stake in EzeRx Health Tech Pvt. Ltd. for INR 290 million.

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) signed a binding letter of intent to acquire remaining 25% stake in Sun Pharma de México, S.A. de C.V. from Indi Pharma S.A.P.I. de C.V. for approximately MXN 160 million.

Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2022-2023

Sun Pharmaceutical Industries Limited Declares Final Dividend for the Financial Year 2022-2023

Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries

Price target increased by 7.0% to ₹1,229

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Sun Pharmaceutical Industries Limited Appealed the Patent Litigation Decision Issued by the US District Court for the District of New Jersey Relating to Orexo's Patents Protecting ZUBSOLV®

Upcoming dividend of ₹4.00 per share at 1.0% yield

High number of new directors

Sun Pharmaceutical Industries Limited to Report Q1, 2024 Results on Aug 03, 2023

Sun Pharmaceutical Industries Limited Propose Final Dividend for Fy2022-23, Payable on or Before September 8, 2023

Orexo AB (publ) Wins Patent Litigation for ZUBSOLV in the US Against Sun Pharmaceutical Industries Limited

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Sun Pharma Canada Inc. Announces Health Canada Approval of (PR)ABSORICA LD®? (Isotretinoin Capsules) for Treatment of Severe Nodular Acne

Sun Pharmaceutical Industries Ltd. Presents Data from First-In-Human Phase 1 Studies of Gl0034 At the American Diabetes Association 83Rd Scientific Sessions

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Sun Pharmaceutical Industries Limited Announces Board Appointments

Sun Pharmaceutical Industries Limited to Report Q4, 2023 Results on May 26, 2023

Sun Pharmaceutical Industries Limited Provides Deuruxolitinib Clinical Program Update

Whole Time Director recently sold ₹3.9m worth of stock

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 27.39% stake in Remidio Innovative Solutions Pvt. Ltd. for INR 1.5 billion.

Sun Pharmaceutical Industries Limited Announces US FDA Approval for Generic Lenalidomide Capsules

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sun Pharmaceutical Industries Limited Announces Retirement of Kalyanasundaram Subramanian as Whole-Time Director, Effective February 13, 2023

Sun Pharmaceutical Industries Limited Launches SEZABYTM (Phenobarbital Sodium) in the U.S. for the Treatment of Neonatal Seizures

Sun Pharmaceutical Industries Limited to Report Q3, 2023 Results on Jan 31, 2023

Sun Pharmaceutical Industries Limited Announces One of Its Wholly-Owned Subsidiaries Launch A Novel Anti-Cancer Drug, Palbociclib in India for Patients

Aurinia Pharmaceuticals Inc. Enters into Settlement Agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE

Whole Time Director recently sold ₹9.2m worth of stock

Insider recently sold ₹3.1m worth of stock

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

Whole Time Director recently sold ₹10m worth of stock

Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures

Second quarter 2023 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited Approves the Appointment of Sanjay Asher as an Additional Director Designated as an Independent Director

Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?

Sun Pharmaceutical Industries Limited to Report Q2, 2023 Results on Nov 01, 2022

Whole Time Director recently sold ₹14m worth of stock

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely

Upcoming dividend of ₹3.00 per share

Sun Pharmaceutical Industries Limited Announces Retirement of Israel Makov as Chairman and Member of the Board

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Year 2021-22, Payable on or Before September 20, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sun Pharmaceutical Industries Limited to Report Q1, 2023 Results on Jul 29, 2022

Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Sun Pharmaceutical Industries Limited Announces Cessation of Mr. Ashok I Bhuta as Compliance Officer

Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?

Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Year Ended March 31, 2022

Full year 2022 earnings: EPS misses analyst expectations

Sun Pharmaceutical Industries Limited to Launch Brillo® in India

Sun Pharmaceutical Industries Limited to Report Q4, 2022 Results on May 30, 2022